Sunflower Pharmaceutical Group (Hengshui) Defeier Co. Ltd.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, the pharmacokinetic behavior of the test preparation oseltamivir phosphate dry suspension (manufacturer: Sunflower Pharmaceutical Group (Hengshui) Defei Co., Ltd.) and the reference preparation oseltamivir phosphate dry suspension (certificate holder: Roche Registration GmbH, trade name: Tamiflu ®) in healthy subjects after oral administration in the fasting/postprandial state was compared to evaluate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation oseltamivir phosphate dry suspension and the reference preparation oseltamivir phosphate dry suspension in healthy subjects.

Main research purpose: Using amoxicillin granules (specification: 0.125 g) provided by Sunflower Pharmaceutical Group (Hengshui) Defeier Co., Ltd. as the test preparation, according to the relevant provisions of the bioequivalence test, the relative bioavailability in healthy humans was compared with amoxicillin fine granules (specification: 100 mg/1 g, trade name: Sawacillin®, reference preparation) produced by LTL ファーマ株式会社 (specification: 100 mg/1 g, trade name: Sawacillin®, reference preparation) to investigate the human bioequivalence of the two preparations. Secondary research purpose: Observe the safety of the test preparation amoxicillin granules and the reference preparation amoxicillin fine granules (trade name: Sawacillin®) in healthy subjects.

Primary Objective: To investigate the absorption rate and extent of absorption of the test and reference formulations under fasting and postprandial conditions after oral administration of a single dose of cefditoren Pivoxil Granules (test formulation T, manufactured and supplied by Sunflower Pharmaceutical Group (Hengshui) Defeier Co., Ltd., specification: 50mg (potency)/0.5g/sachet) and cefditoren Pivoxil Granules (reference formulation R, manufactured by Meiji Seika Pharma Co., Ltd., trade name: Meiact®, specification: 50mg (potency)/0.5g/sachet) to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test and reference formulations of cefditoren Pivoxil Granules in healthy study participants.